Kim Hyungki, Lee Bu-Kyu
Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea.
Department of Stem Cell Center, Asan Institute for Life Science, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Republic of Korea.
Tissue Eng Regen Med. 2020 Jun;17(3):351-362. doi: 10.1007/s13770-020-00268-2. Epub 2020 May 4.
Osteoarthritis (OA) in the temporomandibular joint (TMJ) in the TMJ (TMJ-OA) is difficult to treat, and new alternative treatments are needed. Recently, adipose-derived stem cells (ASCs) have been introduced as a promising cell source because of their anti-inflammatory effects. However, the cost and availability of these cells limited broader applications of stem cell therapy. Thus, Thus, stromal vascular fraction (SVF) containing sufficient amount of ASCs at low cost can be an alternative. In this study, we aimed to demonstrate the use of uncultured, optimally isolated SVF for the treatment of TMJ-OA.
First, we optimized the method of isolation to harvest high-quality SVFs with a large yield of ASCs. Then, we analyzed the quantity of ASCs in the SVF and performed characterization of stem cell homology. Subsequently, to evaluate the anti-inflammatory effect of high-quality SVF, an in vitro study was performed to assess the expression patterns of inflammatory cytokines including prostaglandin E (PGE), IL-6, and CXCL8/IL-8, COX2, TNF, IFN, CCL2/MCP-1 and CCL5/RANTES in co-culture with synoviocytes derived from the synovial fluid in the TMJ-OA patients.
The SVF containing approximately 32% ASCs was isolated via the our optimized isolation method. The SVF significantly down-regulated certain inflammatory cytokines such as PGE2, CXCL8/IL-8 in TMJ-OA tissue-derived synoviocytes.
Although further study is needed, our study suggests that transplantation of adipose tissue-derived SVF cells might be a feasible and a novel therapeutic option for TMJ-OA in the future.
颞下颌关节骨关节炎(TMJ - OA)难以治疗,需要新的替代治疗方法。近年来,脂肪来源干细胞(ASCs)因其抗炎作用被视为一种有前景的细胞来源。然而,这些细胞的成本和可获取性限制了干细胞疗法的广泛应用。因此,以低成本获取含有足够数量ASCs的基质血管成分(SVF)可能是一种替代方法。在本研究中,我们旨在证明使用未经培养、经优化分离的SVF治疗TMJ - OA的可行性。
首先,我们优化了分离方法,以收获高质量、高产量ASCs的SVF。然后,我们分析了SVF中ASCs的数量,并进行了干细胞同源性鉴定。随后,为评估高质量SVF的抗炎作用,我们进行了一项体外研究,以评估与TMJ - OA患者滑液来源的滑膜细胞共培养时,包括前列腺素E(PGE)、白细胞介素 - 6(IL - 6)、CXC趋化因子配体8/白细胞介素 - 8(CXCL8/IL - 8)、环氧化酶2(COX2)、肿瘤坏死因子(TNF)、干扰素(IFN)、单核细胞趋化蛋白 - 1(CCL2/MCP - 1)和调节激活正常T细胞表达和分泌因子(CCL5/RANTES)在内的炎性细胞因子的表达模式。
通过我们优化的分离方法,分离出了含有约32% ASCs的SVF。该SVF显著下调了TMJ - OA组织来源滑膜细胞中某些炎性细胞因子的表达,如PGE2、CXCL8/IL - 8。
尽管仍需进一步研究,但我们的研究表明,脂肪组织来源的SVF细胞移植可能是未来治疗TMJ - OA的一种可行且新颖的治疗选择。